BioCentury
ARTICLE | Company News

Eisai, St. Jude Children's Research Hospital, Medicines for Malaria Venture deal

October 20, 2014 7:00 AM UTC

Eisai partnered with St. Jude and Medicines for Malaria Venture to conduct preclinical and clinical testing of antimalarial compound SJ733. SJ733, a Plasmodium falciparum P-type cation-transporter ATPase 4 (PfATP4) inhibitor, was developed by a consortium of U.S. researchers in academia and non-profit organizations, including St. Jude. The hospital will lead the project, sponsor the IND and be responsible for conducting the Phase I trial. Eisai will coordinate and lead the safety studies as well as scale-up, GMP manufacturing and formulation work. Medicines for Malaria Venture will provide strategic advice and project support in the early stages and then coordinate and lead the Phase Ib trial. The project was granted $3.8 million by the Global Health Innovative Technology Fund (GHIT). ...